ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Potentiation and in vivo evaluation of anti-obesity activity of berberine through encapsulation in guar-acacia gum nanocomplexes.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine is a promising bioactive compound that has gained great attention against numerous diseases but its low solubility and poor systemic bioavailability hinders its clinical applicability. Therefore, this study attempted to enhance the therapeutic potential of berberine by its nanoencapsulation. Berberine loaded guar-acacia gum nanocomplexes (Ber/Gu-AGNCs) were prepared by ionic complexation method; characterized and evaluated for anti-obesity activity in high fat diet (HFD) induced obese rats. HFD was given to animals for 6 consecutive weeks. Orlistat (20 mg/kg, p.o.), berberine (10 mg/kg), Ber/Gu-AGNCs (10 and 20 mg/kg, p.o) and Gu-AGNCs (blank) were administered once a day after giving HFD for 6 weeks; and continued up to 12 weeks along with HFD. Obesity was evaluated by the measurement of morphological parameters, blood glucose, serum lipid profiles, liver enzymes and levels of oxidative stress markers. Moreover, histopathological studies of liver and adipose tissue were also carried out. The results showed that Ber/Gu-AGNCs exhibited spherical morphology and narrow size distribution. In addition, Ber/Gu-AGNCs were significantly more effective in controlling the body weight, body mass index (BMI), adiposity index, liver index, blood glucose levels, serum lipids and oxidative stress levels in comparison to berberine in HFD-induced obese rats. Furthermore, histopathological examination of liver and adipose tissue revealed the anti-obesity effect of Ber/Gu-AGNCs (10 and 20 mg/kg), as indicated by decrease in hepatosteatosis and inflammation in liver tissue; and decrease in the size of adipocytes in fat depots. Thus, nanoencapsulation of berberine into gum nanocomplexes displayed better anti-obesity activity when compared to free berberine.
Indexed as
Identifiers
39715881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.